Clinical application of percutaneous endoscopic gastrostomy ( PEG ) / percutaneous radiologic gastrojejunostomy ( PRGJ ) technology

Objective: The aim of this study was to discuss the indications and efficacy of percutaneous endoscopic gastrostomy (PEG)/percutaneous radiologic gastrojejunostomy (PRGJ). Methods: A total of 104 PEG/PRGJ patients were divided into nervous system disease, digestive system tumor, non-digestive system tumor with eating difficulties, and other type of disease groups. We recorded the longest retained time (LTT), shortest retained time (STT), and average retained time (ATT) of the PEG/PRGJ tubes and compared albumin, pre-albumin, high-sensitivity C-reactive protein (Hs-CRP), the neutrophil-lymphocyte ratio (NLR), hemoglobin level, and Onodera Prognostic Nutrition Index (OPNI) within 1 week before and 4 weeks after catheter retention in the four groups. Results: In the nervous system disease group, mean ATT was 39.8±23.0 months, mean LTT was 60.0 months, and mean STT was 3.0 months. There were significant differences in albumin, Hs-CRP, NLR, and OPNI. In the digestive tract tumor group, the mean ATT was 6.5±2.1 months, mean LTT was 30.0 months, and mean STT was 0.6 months. There were significant differences in albumin and pre-albumin. In the non-digestive tract tumor group, the mean ATT was 18.4±6.8 months, mean LTT was 48.0 months, and mean STT was 3.0 months. There were significant differences in pre-albumin. In the other types of disease group, mean ATT was 29.0±11.3 months, mean LTT was 48.0 months, and mean STT was 24.0 months. There were significant differences in albumin, pre-albumin, and hemoglobin levels. The mean ATT for all patients was 17.8 months, while that for the nervous system group was 18.4 months. The overall complication rate was 13.4%. Conclusion: Nervous system diseases, advanced tumors causing obstruction of the digestive tract or eating difficulties, and some special types of diseases (e.g., short bowel syndrome) may be indications for PEG/ PRGJ.